cp wire

CP Wire Articles

  • Edasalonexent has orphan drug status in the US and Europe
  • It has been fast-track status in the US

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announced on 9/25/18 the... read more

Tue, 09/25/18 - 10:12 am
admin
  • Imfinzi is currently approved in the US for the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and... read more
Tue, 09/25/18 - 09:51 am
admin
  • Alunbrig achieved a 51% increase in progression free survival compared to crizotinib
  • Alunbrig received Breakthrough Therapy Designation from the FDA for the treatment of patients... read more
Tue, 09/25/18 - 09:33 am
admin
  • Oral mucositis is potentially a 1 billion dollar market
  • Additional expenses incurred by patients suffering from SOM are estimated to be as high as $18,000 to $25,000 per case in the... read more
Mon, 09/24/18 - 10:13 am
admin

AstraZeneca on 9/24/18 announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the broadest SGLT-2 inhibitor CVOT... read more

Mon, 09/24/18 - 09:36 am
admin


Gilead Sciences, Inc. (NASDAQ: GILD) announced on 9/24/18 plans to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir... read more

Mon, 09/24/18 - 09:22 am
admin
  • Exelixis is eligible to receive a milestone payment of $40 million for the approval of the second-line treatment of HCC
  • In May of 2018, the FDA accepted for filiing an sNDA for... read more
Fri, 09/21/18 - 09:42 am
admin
  • Company expanding into drug discovery, development and commercialization
  • Ubiome also announced it has raised $83 million in Series C financing


uBiome announced on 9/... read more

Fri, 09/21/18 - 09:15 am
admin


MicuRx Pharmaceuticals, Inc. announced on 9/21/18 the receipt of the qualified infectious disease product (QIDP) classification and grant of fast track... read more

Fri, 09/21/18 - 09:05 am
admin
  • The objective response rate was 29 percent (4 of 22 patients)
  • BeiGene and Celgene Corporation have a global strategic collaboration for the development of tislelizumab in solid tumor... read more
Thu, 09/20/18 - 09:47 am
admin
  • Amicus will make an upfront cash payment of $100 million
  • The company also announced closing a $150 million term loan to help finance the acquisition and development costs
  • ... read more
Thu, 09/20/18 - 09:31 am
admin
  • The vaccine was awarded fast-track status by the FDA in October of 2017
  • Pfizer expects to start Phase 3 trials in a few months


Pfizer Inc. (NYSE:PFE) announced on 9/... read more

Thu, 09/20/18 - 09:08 am
admin

MaaT Pharma announced on 9/18/19 the presentation of the analysis of MaaT Pharma’s lead biotherapeutic, MaaT013, demonstrating its drug product characteristics using MaaT Pharma’s proprietary big... read more

Wed, 09/19/18 - 10:57 pm
admin
  • argynx has 8 drugs in development
  • Partners include Abbvie, LEO Pharma, and Staten Biotech

argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company... read more

Wed, 09/19/18 - 09:32 am
admin
  • Cabometyx has orphan drug status in the US
  • Takeda has rights to all indications for Cabometyx in Japan


Exelixis, Inc.  (NASDAQ:EXEL) announced on 9/19/18 that its... read more

Wed, 09/19/18 - 09:16 am
admin
  • Company received positive written response from FDA regarding development plans
  • Resistant P. aeruginosa is designated as ‘Priority 1: Critical’ pathogen by the World Health... read more
Tue, 09/18/18 - 09:07 am
admin
  • Two of the first four evaluable participants showed tumor regressions at the first on-treatment CT scan
  • DPX-Survivac has received fast-track status from FDA
  • It also has... read more
Tue, 09/18/18 - 08:45 am
admin



AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections... read more

Mon, 09/17/18 - 09:08 am
admin
  • AtomWise raised $45 million in Series A in March of 2018
  • Partners Include: Merck, Abbvie, and Bayer


Atomwise Inc., a leader in Artificial Intelligence (AI) for drug... read more

Mon, 09/17/18 - 08:55 am
admin

Pages

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.